Combination and mutual effect of Alzheimer’s disease and cerebrovascular disease
https://doi.org/10.21518/2079-701X-2019-9-8-13
Abstract
Alzheimer’s disease (AD), cerebrovascular disease and their combination are the most common causes of cognitive impairment (CI) and therefore disability in senior citizens. Mutual influences, manifestations and diagnostics of AD and vascular CI are analyzed. The presence of a vascular component in the development of CI indicates the possibility of their prevention. Treatment of CI is based on correction of vascular factors, non-drug and drug methods to improve cognitive functions. Psychosocial and behavioral methods, cognitive training, central acetylcholinesterase inhibitors and memantine are effective in dementia. The use of cerebrolysine in AD and vascular CI is discussed.
About the Author
V. A. Parfenov
Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University.
Russian Federation
Russian Federation
Dr. of Sci. (Med), Professor, Head of the Department of Nervous Diseases and Neurosurgery of the Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University), Director of the Clinic of Nervous Diseases named after A.Y. Kozhevnikov of the First Moscow State Medical University named after I.M. Sechenov.
References
1. World Health Organization, Alzheimer’s Disease International. Dementia: a public health priority [Internet] Geneva: World Health Organization; 2012.
2. Jellinger K.A. Neuropathology of dementia disorders. J Alzheimers Dis Parkinsonism. 2014;4:1-17.
3. Cerebrovascular disease, cognitive impairment and dementia. Cerebrovascular disease and dementia. 2nd ed. Edited by O’Brien J., Ames D., Gustafson L., et al. London; N.Y.: Martin Dunitz; 2004.
4. Парфенов В.А., Захаров В.В., Преображенская И.С. Когнитивные расстройства. М.: Ремедиум, 2014. 224 с. [Parfenov V.A., Zakharov V.V., Preobrazhenskaya I.S. Cognitive impairments. Moscow: Remedium, 2014. 224 p.] (In Russ.)
5. Gorelick P.B., Scuteri A., Black S.E., et al. Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2011;42: 2672-2713.
6. Sachdev P., Kalaria R., O’Brien J., et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-218.
7. Gutié rrez Pé rez C., Savborg M., Pahlman U., et al. High frequency of cognitive dysfunction before stroke among older people. Int J Geriatr Psychiatry. 2011;26:622-629.
8. Wardlaw J.M., Smith C., Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 2013b;12:483-97.
9. Wardlaw J.M., Valdes Hernandez M.C., Munoz- Maniega S. What are White Matter Hyperinten sities Made of? J Am Heart Assoc. 2015;4(6):e001140.
10. Benedictus M.R., van Harten A.C., Leeuwis A.E. White matter hyperintensities relate to clinical progression in subjective cognitive decline. Stroke. 2015;46:2661-2664.
11. Sun J.H., Tan L., Yu J.T. Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Transl Med. 2014;2 (8):80.
12. Arba F., Quinn T., Hankey G.J., et al. Determinants of post-stroke cognitive impairment: analysis from VISTA. Acta Neurol Scand. 2017;135(6):603-607.
13. Sibolt G., Curtze S., Melkas S., et al. Poststroke de mentia is associated with recurrent ischaemic stroke. J Neurol Neurosurg Psychiatry. 2013;84:722-726.
14. Altieri M., Di Piero V., Pasquini M. et al. Delayed poststroke dementia: a 4-year follow-up study. Neurology. 2004 Jun 22;62(12):2193-2197.
15. Norton S., Matthews F.E., Barnes D.E., et al. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13:788–794.
16. Gottesman R.F., Schneider A.L., Zhou Y., et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. JAMA. 2017;317:1443–1450.
17. Barker W.W., Luis C.A., Kashuba A. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4):203-212.
18. Provenzano F.A., Muraskin J., Tosto G., et al. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol. 2013;70:455–461.
19. Nucera A., Hachinski V. Cerebrovascular and Alzheimer disease: fellow travelers or partners in crime? J Neurochem. 2018 Mar;144(5):513-516.
20. Snyder H.M., Corriveau R.A., Craft S., et al. Vascular Contributions to Cognitive Impairment and Dementia Including Alzheimer’s Disease. Alzheimers Dement. 2015;11(6):710-717.
21. Alvarez X.A., Fuentes P. Cerebrolysin in Alzheimer’s disease. Drugs Today (Barc). 2011;47:487-513.
22. Wei Z.-H., He Q.-B., Wang H. et al. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatement of Alzheimer’s disease. J Neural Transm. 2007;3:84-91.
23. Plosker G.L., Gautheir S. Cerebrolysin: a review of its use in dementia. Drugs Aging. 2009;26:893-915.
24. Chen N., Yang M., Guo J., et al. Cerebrolyzin for VaD. Cochrane Database Syst Rev. 2013;1:CD008900.
25. Bornstein N.M., Guekht A., Vester J. et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018;39:629-640.
26. Alvarez X.A., Alvarez I., Iglesias O. et al. Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases. International Journal of Neuropsychopharmacology. 2016;19(6):1-6.
27. Weinstein G., Beiser A.S., Choi S.H., et al. Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study. JAMA Neurol. 2014;71:55–61.
28. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis. 2008;25:457-507.
29. Gorelick P.B. Blood Pressure and the Prevention of Cognitive Impairment. JAMA Neurol. 2014;71:1211-1213.
30. Ankolekar S., Geeganage C., Anderton P., et al. Clinical trials for preventing post stroke cognitive impairment. J Neurol Sci. 2010;299(1-2):168-174.
31. Cerasuola J.O., Cipriano K.E., Sposato L.A. et al. Population based stroke and dementia incidence trends: age and sex variations. Alzheimers Dement. 2017;10:1081-1088.
Review
For citations:
Parfenov VA. Combination and mutual effect of Alzheimer’s disease and cerebrovascular disease. Meditsinskiy sovet = Medical Council. 2019;(9):8-13. (In Russ.) https://doi.org/10.21518/2079-701X-2019-9-8-13
Views:
703
Email this article 